Micro-X Achieves Major Head CT Milestone Ahead of Australian Imaging Trials

Micro-X Ltd (ASX: MX1), the Australian leader in cold cathode X-ray technology, has completed its first Head CT imaging test system, marking a critical milestone in partnership with the Australian Stroke Alliance (ASA). The device, now ready for hospital installation, has cleared regulatory and ethics approvals, unlocking an AU$0.4 million milestone payment under the ASA contract. The pivotal validation study, to run over six to nine months, will compare Head CT images with conventional scans of stroke patients, advancing Micro-X’s goal of revolutionising stroke diagnosis.

The first system is complete, with two additional test benches under construction for further hospital trials. The Head CT incorporates breakthrough NEX mini-tube technology, high-voltage switching electronics, and a curved detector co-developed with FUJIFILM, delivering diagnostic-quality images at a fraction of conventional radiation doses. Weighing just 70kg, compared to 700kg for standard scanners, the device is designed for deployment in ambulances and aircraft, potentially transforming rapid stroke care globally.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com